ERTUGLIFLOZIN MITIGATES LIVER DAMAGE DURING SEPSIS: EVIDENCE FROM A MURINE MODEL
DOI:
https://doi.org/10.22159/ijap.2026v18i1.56581Keywords:
Ertugliflozin, Extracellular regulated kinases 1/2, Cecal ligation and puncture, Liver damage, SepsisAbstract
Objective: This study sought to examine the liver-protective effects of ertugliflozin in male mice subjected to CLP-induced sepsis.
Methods: Overall, 24 male albino Swiss mice, aged eight to twelve weeks and weighing 25–35 g, were segregated into four separate groups (n=6 each): the Sham, CLP, CLP+DMSO, and CLP+ ertugliflozin groups. In the sham group, the mice were anaesthetized and subjected to laparotomy without cecal ligation and puncture (CLP), whereas in the sepsis group, the mice underwent CLP. The CLP+DMSO group received DMSO (the vehicle for ertugliflozin) through intraperitoneal injection one hour before CLP. In the CLP+ ertugliflozin group, 20 mg/kg was administered via the intraperitoneal method one hour before CLP. Biochemical indicators (GPT, ALT, IL-6, TNFα, MDA, GSH, Bax, pERK1/2, and caspase-3) and histological changes were assessed.
Results: ELISA was used to investigate the levels of the study parameters in hepatic tissues. Compared with those in the sham group, the levels of TNFα, IL6, Bax, caspase3, MDA and phospho-ERK1/2 were significantly elevated in the mice subjected to sepsis via caecal ligation and puncture (CLP), whereas the GSH level was significantly decreased. In contrast, treatment of septic mice with ertugliflozin significantly reduced these parameters in comparison with those of the sepsis group. Furthermore, histopathological examination revealed that the occurrence of sepsis via CLP resulted in significant liver damage compared with that in the sham group. Conversely, the treatment of mice subjected to CLP with ertugliflozin significantly mitigated liver injury.
Conclusion: Ertugliflozin, which inhibits SGLT2, has significant hepatoprotective effects on CLP-induced sepsis, mainly via its antioxidant, anti-inflammatory, and antiapoptotic effects.
References
1. Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis: current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259–72.
2. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762–74.
3. Saini K, Bolia R, Bhat NK. Incidence, predictors and outcome of sepsis-associated liver injury in children: a prospective observational study. Eur J Pediatr. 2022;181(4):1699–707.
4. Woźnica EA, Inglot M, Woźnica RK, Łysenko L. Liver dysfunction in sepsis. Adv Clin Exp Med. 2018;27(4):547–51.
5. Yan J, Li S, Li S. The role of the liver in sepsis. Int Rev Immunol. 2014;33(6):498–510.
6. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G, et al. Current gaps in sepsis immunology: new opportunities for translational research. Lancet Infect Dis. 2019;19(12): e422–36.
7. Traeger T, Kessler W, Hildebrand F, Regel G, Menges T, Flohé S, et al. Kupffer cell depletion reduces hepatic inflammation and apoptosis but decreases survival in abdominal sepsis. Eur J Gastroenterol Hepatol. 2010;22(9):1039–49.
8. Waseem N, Chen PH. Hypoxic hepatitis: a review and clinical update. J Clin Transl Hepatol. 2016;4(3):263–8.
9. La Mura V, Pasarin M, Meireles CZ, Rodriguez-Vilarrupla A, Garcia-Pagan JC, Bosch J, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology. 2013;57(3):1172–81.
10. Strnad P, Tacke F, Koch A, Trautwein C. Liver—guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14(1):55–66.
11. Jia Y, Li Z, Feng Y, Cui R, Dong Y, Zhang X, et al. Methane-rich saline ameliorates sepsis-induced acute kidney injury through anti-inflammation, antioxidative, and antiapoptotic effects by regulating endoplasmic reticulum stress. Oxid Med Cell Longev. 2018;2018:4756846.
12. Qassam H, Janabi AM, Gaen KK, et al. Dimethyl fumarate attenuates liver injury in a mouse model of cecal ligation and puncture by modulating inflammatory, angiogenic and pyroptotic pathways. BMC Pharmacol Toxicol. 2025; 26:134.
13. Jeong SJ, Han SH, Kim CO, Choi JY, Kim JM. Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care. 2013;17(1): R97.
14. Ibrahim Y, Amin EF, Kamel MY, Ahmed LA, Mohamed MA, Abdelrahman AM, et al. Protective effect of febuxostat in sepsis-induced liver and kidney injuries after cecal ligation and puncture with the impact of xanthine oxidase, interleukin 1 β, and c-Jun N-terminal kinases. Hum Exp Toxicol. 2020;39(7):906–19.
15. Siempos II, Maniatis NA, Kopterides P, Magkou C, Glynos C, Armaganidis A, et al. Cecal ligation and puncture-induced sepsis as a model to study autophagy in mice. J Vis Exp. 2014;(84): e51066.
16. Abd Uljaleel A, Hassan E. Protective effect of ertugliflozin against acute lung injury caused by endotoxemia model in mice. Iran J War Public Health. 2023;15(1):67–75.
17. Alaasam ER, Janabi AM, Mahmoud SS, El-Mahdy NA, Al-Buthabhak KM, Almudhafar RH, et al. Nephroprotective role of resveratrol in renal ischemia‒reperfusion injury: a preclinical study in Sprague‒Dawley rats. BMC Pharmacol Toxicol. 2024;25(1):82.
18. Alkhafaji GA, Janabi AM. GIP/GLP-1 dual agonist tirzepatide ameliorates renal ischemia/reperfusion damage in rats. Int J App Pharm. 2025;17(2):165–73.
19. Jallawee HQ, Janabi AM. Trandolapril improves renal ischemia‒reperfusion injury in adult male rats via activation of the autophagy pathway and inhibition of inflammation, oxidative stress, and apoptosis. J Biosci Appl Res. 2024;10(6):114–27.
20. Alkhafaji GA, Janabi AM. Protective effects of bexagliflozin on renal function in a rat model of ischemia‒reperfusion injury: an experimental animal study. J Nephropharmacol. 2025;14(2):e12760.
21. Tiba AT, Qassam H, Hadi NR. Semaglutide in renal ischaemia‒reperfusion injury in mice. J Med Life. 2023;16(2):317–24.
22. Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med. 2023;23(2):273–85.
23. Esmon CT, Taylor FB Jr, Snow TR, Taylor SL, Taylor SM, Taylor DR, et al. Inflammation, sepsis, and coagulation. Haematologica. 1999;84(3):254–9.
24. Jacobi J. Pathophysiology of sepsis. Am J Health Syst Pharm. 2002;59 Suppl 1:S3–8.
25. Kobashi H, Toshimori J, Yamamoto K. Sepsis-associated liver injury: incidence, classification and the clinical significance. Hepatol Res. 2013;43(3):255–66.
26. Jeschke MG, Finnerty CC, Kulp GA, Kraft R, Mlcak RP, Herndon DN. Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J Hepatol. 2005;42(6):870–9.
27. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Buchman TG. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A. 1999;96(25):14541–6.
28. Pettilä V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med. 2002;28(8):1220–5.
29. Kareem RT, Abass MK. A potential anti-inflammatory effect of ertugliflozin in animal model. South Asian Res J Pharm Sci. 2024;6(3):84–8.
30. Alaasam ER, Janabi AM. Erythropoietin protects against renal ischemia/reperfusion injury in rats via inhibition of oxidative stress, inflammation and apoptosis. J Contemp Med Sci. 2023;9(4):233–8.
31. Alsaaty EH, Janabi AM. Moexipril improves renal ischemia/reperfusion injury in adult male rats. J Contemp Med Sci. 2024;10(1):25–30.
32. Llorens-Cebrià C, Molina-Van den Bosch M, Vergara A, Jacobs-Cachá C, Soler MJ. Antioxidant roles of SGLT2 inhibitors in the kidney. Biomolecules. 2022;12(1):143.
33. Gao X, Wu L, Ouyang W, Li Y, Xu Y, Wang Y. Therapeutic targeting of apoptosis inhibitor of macrophage/CD5L in sepsis. Am J Respir Cell Mol Biol. 2019;60(3):323–34.
34. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol. 2002;37(3):400–10.
35. Mohammad A, Khazaal E, Al-Jubouri A, Al-Saadi A, Al-Mudhaffer A, Al-Ali A. Protective effect of ipragliflozin on acute brain injury induced by endotoxemia in mice. Iran J War Public Health. 2023;15(3):225–31.
36. Park GB, Kim D, Kim YS, Kim D, Kim Y, Kim Y. ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells. Int J Oncol. 2014;44(3):977–85.
37. Haddad JJ. The role of Bax/Bcl-2 and pro-caspase peptides in hypoxia/reperfusion-dependent regulation of MAPKERK: discordant proteomic effect of MAPKp38. Protein Pept Lett. 2007;14(4):361–71.
38. Li S, Wang Y, Zhang J, Lu Y, Zhang Y, Wang Y. Astaxanthin prevents ischemia‒reperfusion injury of the steatotic liver in mice. PLoS One. 2017;12(11): e0187810.
39. Hong JM, Kim SJ, Lee SM. Role of necroptosis in autophagy signaling during hepatic ischemia and reperfusion. Toxicol Appl Pharmacol. 2016; 308:1–10.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SALSABEEL H. ALRUFAIE, ALI M. JANABI
This work is licensed under a Creative Commons Attribution 4.0 International License.
